Delving into the Latest Updates on Institut Servier de Medecine Translationnelle SARL with Synapse

Overview

Basic Info

Introduction

Adir, a subsidiary of Servier SAS, is an organization based in Suresnes, France that specializes in biological research and development.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Small molecule drug

Universal CAR-T

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Hemic and Lymphatic Diseases	4
Immune System Diseases	2
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	3
Monoclonal antibody	2
Universal CAR-T	1
Enzyme	1

Top 5 Target	Count

PD-1(Programmed cell death protein 1)	1
Bcl-2(Apoptosis regulator Bcl-2)	1
ASN(Asparagine)	1
HLA-E x NKG2A	1
CD19(B-lymphocyte antigen CD19)	1

A Randomised, Open-label, Multi-centre, Two-arm Phase 3 Study Comparing Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil to Trifluridine/Tipiracil Single Agent With a Safety Lead-In Part in Participants With KRAS/NRAS and BRAF Wild Type Metastatic Colorectal Cancer Previously Treated With Standard Treatment and Anti-EGFR Therapy

This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT).

Start Date21 Apr 2022

Sponsor / Collaborator

Institut de Recherches Intern Servier

[+1]

100 Clinical Results associated with Institut Servier de Medecine Translationnelle SARL

Login to view more data

0 Patents (Medical) associated with Institut Servier de Medecine Translationnelle SARL

Login to view more data

100 Deals associated with Institut Servier de Medecine Translationnelle SARL

Login to view more data

100 Translational Medicine associated with Institut Servier de Medecine Translationnelle SARL

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

3

2

Phase 2

Phase 3

2

14

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tipiracil Hydrochloride/Trifluridine ( TYMP x TYMS )	Metastatic Colorectal Carcinoma More	Phase 3
Calaspargase Pegol-MKNL ( ASN )	Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia More	Phase 2/3
VOB-560 ( Bcl-2 )	Acute Myeloid Leukemia More	Phase 1/2
ALLO-501 ( CD19 )	Lymphoid Leukemia More	Phase 1
S-095029 ( HLA-E x NKG2A )	Advanced Malignant Solid Neoplasm More	Phase 1